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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract Metastasis is a major cause of cancer deaths. Seeking alternative prognostic bio-
markers may enable oncologists to make accurate therapeutic decisions to benefit cancer pa-
tients. Cumulated evidence reveals that fibronectin (FN) is highly correlated with cancer
metastasis but has not been deemed as a prognostic biomarker due to its broad tissue distri-
bution patterns and complicated physiological and pathological functionalities that signifi-
cantly interfere with the judgmental accuracy. Combining other FN-related factors may
make FN possible as a useful prognostic biomarker. Clathrin, a highly protease-susceptible
cytoplasmic molecule, is known to affect pericellular FN (periFN) assembly via regulating cell
surface FN receptors or FN matrix turnover by coating the endocytic vesicles. Researching our
previously published proteomics database of 660 differential secretome proteins expressed in
human lung adenocarcinoma cell lines and performing double immunofluorescent staining for
periFN and clathrin, we recognized an inverse relationship between them. However, sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) data contradicted this relation-
ship, which could be corrected by the addition of a mixture of protease inhibitors into nonme-
tastatic cancer cell lysates. These results suggested that nonmetastatic cells express either
higher levels of cellular proteases or less amounts of protease inhibitors. By examining our pro-
teomic database and reviewing the literature, we conclude that clathrin expression and as-
sembly is inversely correlated with metastatic potential of FNhigh cancer cells mainly related
to the expression of protease inhibitors, instead of proteases. It is worth investigating whethert of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University,
an.
u.edu.tw (H.-C. Cheng).
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24 C.-I. Wu et al.such an inverse relationship between FN/protease inhibitors and clathrin in human cancers
could clinically be incorporated into the prognostic strategy for various cancer types.
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Metastasis is the major cause of cancer death.1,2 Predic-
tion of the cancer malignancy at cancer patients’ early-
onset time may benefit patients by enabling a suitable
cancer therapeutic strategy.3 Unfortunately, clinical and
pathological staging proved to be less beneficial.3 Seeking
alternative prognostic biomarkers has thus become urgent
to help oncologists make accurate and appropriate ther-
apeutic decisions and to prevent increasing cancer mor-
tality.4 Recently, accumulating cancer research findings
have indicated that fibronectin (FN) expression in various
tumor cells is highly correlated with malignant phenotypes
and poor prognosis.5e9 Therefore, it seems that FN could
serve as an ideal prognostic biomarker for predicting the
tumor progressive outcomes.5,9 We have previously
examined the differential protein expressions in a pair of
human lung adenocarcinoma cell lines using the prote-
omics analysis methodology and identified pericellular FN
(periFN) assembly as an important pro-metastatic cellular
activity.10 However, due to the broad tissue distribution
patterns and complicated physiological and pathological
functions of FN,6 it is difficult to make a clear diagnostic
judgment solely by the FN expression profile on clinical
tumor samples as to the effects of FN on tumor progres-
sion.2 Nevertheless, the ultimate goal of using FN as a
prognostic biomarker may still be made possible through
combining other FN-related factors. Clathrin-dependent
endocytosis is essential for the periFN assembly on
tumor cell surfaces, either by regulating the activities of
cell surface FN receptors, e.g., integrins, or by influencing
periFN turnover.11,12 Importantly, clathrin proteins are
known to be highly susceptible to proteolytic cleavages.13
Here, we further looked into our previous proteomic
database10 and recognized the upregulation of protease
inhibitors in highly metastatic and clathrin heavy chain in
non-metastatic lung cancer cell lines.10 This article sys-
tematically reviews and integrates the scientific
consensus from literature to solve the seemingly contra-
dicted results regarding the relationship between clathrin
expression and periFN-promoted cancer metastasis and,
based on our results, to rationalize how expression of
cellular protease inhibitors, rather than proteases, could
contribute to the metastatic phenotypes of cancer cells
for future prognostic purposes. Altogether, we propose
that high levels of periFN expression/assembly and pro-
tease inhibitors may be combined with decreased clathrin
expression to serve as concerted malignancy-prognostic
biomarkers, which warrants further scientific in-
vestigations and scrutiny.FN and cancer metastasis
FN plays an important role in mediating tumor progression
due to its high abundance within extracellular matrices, in
the circulation, and on tumor cell surfaces, and its inter-
action with various cellular components.14e16 Cumulated
evidence manifests the promoting role of FN in cancer
metastasis.1e3,5e9,17e19 We have shown that suspended
cancer periFN matrix assembly is required for cancer
metastasis via adhering to endothelial dipeptidyl peptidase
IV (DPP IV).6,8,17 The specificity of DPP IV/periFN adhesion
in cancer metastasis was demonstrated with the reduced
metastatic ability of the tumor cells pretreated with solu-
ble DPP IV prior to intravenous injection,6,20 or with that
injected into Fischer 344/CRJ rats, a Fischer 344 rat sub-
strain with a significantly decreased lung endothelial DPP IV
expression.21 We further employed proteomics analytical
tools to investigate how periFN assembly is regulated and
identified a trypsin inhibitor, a1 antitrypsin (A1AT; serpine
A1) within secretomes of lung adenocarcinoma cells as a
required extracellular regulatory protein.10 Others have
also continued to use genomic as well as proteomics ap-
proaches and provide evidence that FN expression in cancer
cells is highly correlated with cancer metastatic potential
and poor prognosis.2,4,9,18,22e24 For example, by genomi-
cally analyzing highly metastatic melanoma cancer cells
that were selected with an in vivo scheme, FN was identi-
fied on the top of a list of gene expressions that correlates
with progression to a metastatic phenotype.2 In the SATB1-
reprogramming repertoire that leads to breast tumor
growth and metastasis, FN was genomically identified as a
highly upregulated gene.22 For renal cell carcinoma pa-
tients, elevated plasma levels of cellular FN, which nor-
mally is not present in the plasma, is acceptable and useful
as a follow-up prognostic tool to predict more advanced
diseases.18,19 Using proteomics analyses on microvesicular
proteins secreted by human breast cancer cells and glioma
cells and body fluid, i.e., urine, from human bladder cancer
patients, FN has been highly correlated with tumor meta-
static ability and poor prognosis.23,24Regulations of periFN assembly and
endocytosis
FN matrix assembly is an outcome of steady dynamics and
could be augmented by binding of soluble FN to cell surface
FN receptors, e.g., integrins a5b1, aIIBb3, avb3, or synde-
cans, via inside-out signaling regulation of FN receptor
activity.25e27 Conversely, the established periFN matrices
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mechanisms.11,28e30 Tendency toward the balancing end of
periFN augmentation or turnover critically determines the
degree to which periFN is assembled. Endocytosis of
receptor-associated FN or of FN receptors may negatively
impact periFN assembly.28,30 Although FN matrix turnover
that is caused by caveolin-dependent endocytosis has been
evidenced,30 both caveolin- and clathrin-dependent endo-
cytic pathways are involved in the endocytosis of FN-
receptors (integrins).31e34 Indeed, using immunocyto-
chemical staining techniques, FN is found to be colocalized
with clathrin as well as caveolin within cytoplasm,12 arguing
that, like FN receptors, FN may directly be internalized
through both clathrin-dependent and -independent path-
ways. By contrast, endocytic activity of tumor cells could
be directed by the outside-in signaling pathways descen-
dent from FN-receptor/FN matrix assembly.35e38 In line
with these findings, clathrin-mediated endocytosis of
transmembrane proteins, membrane-associated proteins,
and extracellular components that are capable of binding
to cell surface receptors could be regulated by signaling
regulators such as RhoA small GTPase, p130Cas, focal
adhesion, integrin-linked kinase (ILK), microtubules, or
actin stress fibers, which are all reported to be downstream
effectors from integrin/FN matrix binding.39e46Inverse correlation between clathrin
expression and periFN assembly
Since clathrin may directly or indirectly influence endocy-
tosis of FN matrix and vice versa, promoted clathrin-
dependent endocytosis likely disfavors periFN assembly.
This hypothesis is supported by our previous proteomics
analyses on human lung adenocarcinoma cells, in which
clathrin heavy chain was found upregulated in non-
metastatic CL1-0 cells, but downregulated in metastatic
CL1-5 cells, with differential expression of two point one-
fold10 (Table 1). Indeed, we employed double immunoflu-
orescent staining methodology and found that periFN as-
semblies of suspended human lung cancer cell lines, FNhigh
metastatic CL1-5 and FNlow nonmetastatic CL1-0 cells,10
were inversely correlated with the expression levels ofTable 1 High expression levels of proteases, protease in-
hibitors, and clathrin in CL1-0 cells (fold-change  2).
Protein types CL1-0/CL1-5
expression
fold-change
Proteases
XPNPEP1 (Xaa-Pro aminopeptidase 1) 3.8
LAP3 (cytosol aminopeptidase) 3.5
PEPD (Xaa-Pro dipeptidase) 2.7
NLN (neurolysin, mitochondrial) 2.2
RNPEP (aminopeptidase B) 2.2
Protease inhibitors
TIMP2 (metalloproteinase inhibitor 2) 2.0
Clathrin protein
CLTC (clathrin heavy chain 1) 2.1clathrin (Fig. 1). Surprisingly, when we used immunoblot-
ting assays to confirm such a correlation, we found that two
apparent clathrin bands with 116 kDa and 59 kDa appeared
in CL1-5 cell lysates with larger quantities than those in
CL1-0 cell lysates, contradictive to the aforementioned
inverse correlation (Fig. 2; left panel). Compared to the
results from immunoblotting assays, which detect proteins
prepared from cell lysates and subjected to diverse spectra
of proteases,13 immunofluorescent staining detects intact
cellular proteins fixed right at where they are.13,47,48
Therefore, one would expect that clathrin is more vulner-
able to the elevated activity of cellular protease digestion
in the lysates of CL1-0 than in those of CL1-5 cells. Such
speculation is strongly supported by examining the differ-
ential expression of proteases and protease inhibitors in the
proteomic data yielded from the secretomes of CL1-0 and
CL1-5 cells.10Proteolytic susceptibility of clathrin in low
metastatic cancer cells
Cellular proteolysis is a highly coordinated process that
functions in virtually all compartments of cells.49 Cellular
proteases include exopeptidases, the activities of which are
directed by the N- or C-terminus of the peptide, and en-
dopeptidases, which usually do not accommodate the
charged N- or C-termini amino acids at the active site, but
internally cleave the peptide bonds in substrate poly-
peptides.49,50 In general, endopeptidases, instead of exo-
peptidases, are alternatively termed proteinase.49
Endopeptidases are classified according to the essential
catalytic amino acids at their active sites. Six classes of
proteinases are identified and defined: serine, threonine,
glutamic, cysteine, aspartic, and metalloproteinases (see
reviews elsewhere).50e52 Generally, mammalian serine
proteinases are found in secretory granules or specialized
granules (e.g., azurophil granules).49 Many of these serine
proteinases are general and non-specific proteases. Like
serine proteinases, most of the cysteine proteinases have
general proteinase activity, likely involved in the initial or
terminal stages of extensive degradation of proteins.
Cysteine proteinases are often found in the cytosol or in
lysosomes, functioning right within the in situ compart-
ments.49 Aspartic proteinases are located in secretory
granules, membranes, endosomes, or lysosomes.49 Threo-
nine proteinases are mainly located in ubiquitin-directed
proteasomes.53 Compared to serine and cysteine pro-
teinases, the species of threonine and aspartic proteinases
are significantly fewer.49,53 The metal ion conjugates
mainly appear within endoplasmic reticulum, the plasma
membrane, mitochondria, and the cytosol. Metal-
loproteinases are involved in the removal of signal peptides
and peptide processing, inactivation of biologically active
peptides, and hydrolysis of proteins associated with mem-
branes or extracellular matrix proteins, which are known to
critically contribute to the tumor migration and invasion.49
Additionally, there are some proteinases of unknown cat-
alytic mechanism assigned to a new, temporary subclass:
EC 3.4.99.49,52 This subclass accommodates enzymes either
not sufficiently purified to allow traditional assignation or
apparently do not fit one of the six classical groups.49,52
Figure 1 Inverse relationship between clathrin expression and pericellular fibronectin (periFN) assembly. (A) Two representative
double immunofluorescent staining for clathrin (green) and FN (red) of CL1-0 and CL1-5 cells (magnitude: 400 ); (B) dot plot
quantifications of (A) with fluorescence activated cell sorting analysis. Dots within green and red rectangles represent the per-
centages of total clathrin-positive and FN-positive cells, respectively.
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teolytic digestion originated from experimental designing in
acquiring clathrin proteolytic fragments for the structural
studies of the clathrin triskelion assembling mechanism.13
The details of the clathrin triskelion structure have been
previously reviewed and are not in the scope of this re-
view.54,55 Upon digestion at room temperature with serine
proteinases (chymotrypsin, elastase, subtilisin BPN, and
trypsin), metalloproteinase (thermolysin), and cysteine
proteinase (papain) and sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) analysis of
cleavage patterns on clathrin trimers and clathrin cages,
the light chains are extremely susceptible, but the heavy
chains are more resistant to proteolytic degradation,
yielding two families of peptides.13,47 The first larger-size
family of fragments with 130,000, 116,000, 105,000, and
90,000 Mr. and the second family of peptides with smaller
sizes, w59,000, 52,000, and 41,000 Mr. reflect that the
clathrin heavy chain is vulnerable to almost all types of
proteases, attacking preferentially the same subset of
cleavage regions.13 Indeed, the above-depicted 116,000,
59,000, and 41,000 Mr. and two unprecedented low mo-
lecular weight (low MW) fragments were recognized in our
SDS-PAGE anti-clathrin heavy chain immunoblotting (Fig. 2;
left panel). While the 116,000 and 59,000 Mr. fragments
apparently appeared in a larger quantity in the CL1-0 than
the CL1-5 cell lysates, the two low MW fragments
conversely existed to a greater extent in the CL1-5 celllysates (Fig. 2; left panel), suggesting either that the CL1-
0 cells express higher levels of cellular proteases and/or
that CL1-5 cells express higher levels of protease inhibitors.
The latter possibility is strongly substantiated by the fact
that the species numbers and the expression levels of
protease inhibitors, but not of proteases, are higher in CL1-
5 than in CL1-0 cells (Tables 1 and 2) and the evidence that
a mixture of protease inhibitors significantly diminished the
protein ratios of the lower band of low MW fragments and
increased those of the higher band of low MW fragments as
well as 41,000, 59,000, and 116,000 Mr. fragments and the
full-length 180,000 Mr. clathrin heavy chain in CL1-0 cell
lysates (Fig. 2). Consequently, the larger protein frag-
ments, including the full-length clathrin, in CL1-0 lysates
became more abundant than those in CL1-5 lysates upon
administration of protease inhibitors (Fig. 2; right panel),
rendering the consistent inverse correlation between sus-
pended periFN assembly and clathrin expression as shown
by the immunofluorescent staining (Fig. 1). The notion that
proteolytic clathrin fragments remained after the treat-
ment of protease inhibitors could be well explained by the
fact that some proteolytic enzymes do not appear to be
inhibited by any of the classical protease inhibitors and
these might represent a new mechanistic class of pro-
teinases as described above.49,52 Indeed, in our recent
studies, we found that A1AT is highly expressed in the
secretome from CL1-5 cells.10 A1AT is capable of triggering
cancer metastasis via promoting suspended periFN on CL1-5
Figure 2 Clathrin expressions in CL1-5 and CL1-0 cells
without (w/o; left panel) and with (w/; right panel) a cocktail
of protease inhibitors. Immunoblotting with rabbit pAb (pAb sc-
9069; Santa Cruz Biotechniques, Santa Cruz, CA, USA) against
clathrin heavy chain expressed by CL1-5 and CL1-0 cells. Note:
the major clathrin full-length protein (180 kDa; represented by
the red asterisk) and 116 kDa, 59 kDa, 41 kDa, and two low-MW
proteolytic fragments are depicted by arrows.
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inhibitors such as A1AT in the CL1-5 cell lysates inhibits the
proteolysis of clathrin proteins, but CL1-0 lysates fail to
exert the same inhibition due to the lower expression of
such protease inhibitors. Expectedly, addition of excessTable 2 High expression levels of proteases and protease
inhibitors in CL1-5 cells (fold-change  2).
Protein types CL1-5/CL1-0
expression
fold-change
Protease inhibitors
SERPINA1 (alpha-1-antitrypsin) 56.3
SERPINE2 (glia-derived nexin) 15.4
SERPINA3 (alpha-1-antichymotrypsin) 11.6
SERPINE1 (plasminogen activator
inhibitor 1)
3.5
SERPINI1 (neuroserpin) 2.0
Proteases
MMP2 (72 kDa type IV collagenase) 70.8
CTSB (cathepsin B) 27.0
MMP1 (interstitial collagenase) 21.2
CTSL1 (cathepsin L1) 15.3
CPD (carboxypeptidase D) 13.3
CTSD (cathepsin D) 10.2
SCPEP1 (retinoid-inducible serine
carboxypeptidase)
10.0
CTSZ (cathepsin Z) 8.0
CPVL (probable serine
carboxypeptidase CPVL)
6.6
PRSS23 (serine protease 23) 3.8
ANPEP (aminopeptidase N) 3.1
CPE (carboxypeptidase E) 2.2amount of protease inhibitors to the CL1-0 cell lysates
partially, yet significantly, stops the proteolytic activities
for clathrin proteins (Fig. 2).
Although there have been attempts to correlate FN and
clathrin heavy chain with cancer metastasis and metastasis-
free survival,3,5e8,10,18,19,56e58 the effort of employing FN
and clathrin as combined biomarkers in cancer patient
prognosis has never been exerted. It would be of interest to
see such an effort being clinically practiced in the future.
Based on the above observations, we speculate that it is
likely that the protease inhibitors play a major role in
promoting cancer metastasis and in preventing proteins
from proteolytic cleavage in the CL1-5 cell lysates.Increased levels of protease inhibitors in FNhigh
metastatic cancer cells
Provided that the higher level of trypsin (a serine protease)
inhibitor A1AT expressed in the secretomes of CL1-5 cells
was identified with the label-free quantitative proteomics
approach,10 we were interested to know how all types of
proteases and corresponding protease inhibitors in these
two human lung adenocarcinoma cells are differentially
expressed. We therefore searched the 660 unique differ-
entially expressed proteins that were significantly identi-
fied by normalizing proteins between the CL1-0 and CL1-5
cells, to determine a global scaling factor in Progenesis
LC-MS software, Nonlinear USA Inc., Durham, NC 27713,
USA.10 We set a criteria of fold-change greater than two for
the differential expression. We found that five protease
inhibitors (3 out of 5 even with fold-change >10) were
highly expressed in CL1-5 cells, but only one with fold-
change barely greater than two in CL1-0 cells. Conversely,
various proteases are overexpressed in both CL1-5 and CL1-
0 cells, particularly with higher abundancy in protease
types and expression levels in CL1-5 cells (Tables 1 and 2).
Importantly, all of the identified protease inhibitors, spe-
cifically for metalloproteinases and serine proteases
including A1AT, were associated with the malignant phe-
notypes for various types of cancers.10,59e65 By contrast,
the proteases highly expressed in CL1-5 cells were consis-
tently found to be critical for cancer metastasis,66e69 but
only a few upregulated proteases in CL1-0 cells known to
suppress tumor malignancy.70,71
Among those tumor malignancy-associated inhibitors
highly expressed in CL1-5 cells, A1AT (SERPINA1) has been
found in the secretomes of not only lung adenocarcinoma
cells,10 but also colorectal and renal adenocarcinoma
cells.61 In addition to the enhancement of suspended per-
iFN assembly, A1AT could inhibit natural killer cytotox-
icity,59 likely modulating host innate immunosurveillance in
favor of tumor progression and metastasis.60 Elevated
protease nexin-1 (PN-1; SERPINE2), the phylogenetically
closest relative of plasminogen activator inhibitor-1 (PAI-1;
SERPINE1), blocks urokinase plasminogen activator (uPA),
tissue-specific plasminogen activator (tPA), thrombin, fac-
tor XIa, prostasin, and trypsin activity, and has been found
highly correlated with breast cancer metastasis to the
lungs,63,72 suggesting that it contributes to the tumor cell
motility and metastatic spread via regulating uPA.72 More-
over, PN-1 triggers extracellular matrix assemblies,
Figure 3 The clathrin expression and assembly is inversely correlated with metastatic potential of FNhigh cancer cells mainly
related to the expression of protease inhibitors, instead of proteases. The higher expression and assembly levels of clathrin within
live CL1-0 non-metastatic FNlow cancer cells (as shown in Fig. 1), which express lower levels of endogenous protease inhibitors, are
more susceptible to the proteolytic degradation in the cell lysates (as shown in the left panel of Fig. 2).
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vasion of pancreatic cancer, representing a valuable
experimental design for the study of tumor-stroma in-
teractions.63 Neuroserpin (PI-12; protease inhibitor-12;
SERPINI1), an inhibitor of tPA primarily expressed in the
brain, is released from neurons in regulating proteolytic
activity upon neuronal depolarization that is important for
the functions of nervous system.73 Using GeneChip analysis
on high grade human prostate cancer, neuroserpin has been
identified as a survival factor.65 Neuroserpin has been re-
ported to be associated with poor prognosis in prostate
cancer patients resistant to radical prostatectomy or hor-
mone therapy.65. In line with the findings for PN-1 and
neuroserpin, PAI-1 inhibits uPA by forming a covalent
complex, thus blocking interactions between uPA and its
substrates.74 Likewise, PAI-1 may have a role in regulating
tumor invasion, angiogenesis, and metastasis, because
raised levels of PAI-1 are associated with a poor prognosis in
many cancer types, including breast cancer, melanoma,
and neuroblastoma.74e76 Alpha 1 antichymotrypsin (SER-
PINA3), a serine protease inhibitor, is aberrantly expressed
in tissues of malignant melanoma cells as identified in the
gene expression profiling experiments.77 Validated in the
xenograft mouse model, alpha 1 antichymotrypsin is pre-
sent in serum of mice carrying the human malignant mel-
anoma cell line.77 Consistently, it has been reported that
alpha 1 antichymotrypsin can serve as a predictor of early
tumor recurrence in patients with invasive breast cancers
after therapeutic treatments.78 Other than the identified
protease inhibitors, accumulating data reveal that expres-
sion of protease inhibitors in metastatic cancer cells may
facilitate self-progression and protect protease attackingfrom either metastatic-suppressive activities of tumor cells
or from host tumor microenvironments.79e82 Collectively,
our data and others’ data firmly suggest that FN, when
combined with multiple cellular protease inhibitors, could
serve as an ideal metastatic prognostic biomarker. These
possibilities should be further preclinically tested before
clinical applications.The role of protease in tumor malignancy is
relatively controversial
In contrast to the ample evidence for the role of protease
inhibitors in promoting tumor malignancy, the roles of the
identified proteases in suppressing tumor progression have
been less addressed, except neurolysin and LAP3,70,71
which inhibit in vivo melanoma tumor growth and
enhance apoptotic effects of human breast cancer cells,
respectively. Moreover, compared to the three out of the
five protease inhibitors identified in CL1-5 cells, which
exhibit a >10-fold change, all the upregulated proteases
identified in CL1-0 cells only show a three-fold change,
inferring that it is the raised expression of protease in-
hibitors, but not reduced proteases, in metastatic cancer
cells that mainly contribute to the cancer malignant phe-
notypes. These results could be rationalized by the fact
that, since all the proteases are physiologically involved in
extremely diverse intracellular as well as extracellular ac-
tivities, including complex metabolic pathways and host
immunosurveillance systems,50,83 catastrophes could be
expected if protease expression is elevated or reduced too
much. Nevertheless, despite the lack of solid evidence for
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CL1-0 cells in tumor progression (Table 1), there are still
other proteases reported to be highly expressed in the low
metastatic cancer cells.84 For example, DPP IV, a type II
transmembrane serine exodipeptidyl peptidase capable of
cleaving X-pro dipeptides from the N-terminus of substrate
proteins, has been found downregulated in the invasive
tumor cells, thus serving as a tumor suppressor gene.84 The
downregulation of cysteine protease cathepsin L or pro-
apoptotic protease caspase-3, -5, -6, -7, -8, or -10 pro-
motes tumor progression and malignant transformation.84
Conversely, elevated serine protease HtrA1 inhibits inva-
siveness of esophageal squamous cell carcinoma.85 How-
ever, the role of cancer-derived proteases in tumor
progression is relatively controversial, in that many pro-
teases and protease-related proteins, including those
identified in CL1-5 cells, have been found to play a major
pro-malignant role in tumor progression,86,87 arguing the
true clinical significance of proteases. Such controversy
regarding proteases warrants further elucidation of the
most appropriate regulatory roles of protease and protease
inhibitors in tumor progression.
Conclusion
By proteomics analyses on differential expression data-
bases, treating human lung adenocarcinoma CL1-0 cells
with a cocktail of protease inhibitors, and literature surf-
ing, it is tempting to conclude that the clathrin expression
and assembly is inversely correlated with the metastatic
potential of FNhigh cancer cells mainly related to expression
of protease inhibitors, instead of proteases (Fig. 3). The
impacts of various protease inhibitors on tumor malignancy
have continuously been demonstrated in diverse types of
tumor. Those tumor type-specific protease inhibitors are
therefore suitable to be developed as prognostic bio-
markers. By contrast, intracellular proteases may not be
appropriate for use in predicting tumor progression stages
due to their involvements in great varieties of cellular ac-
tivities as well as tissue remodeling. Finally, although FN
expression in cancer cells has often been shown to be highly
correlated with tumor malignancy, it has rarely been used
as a useful prognostic biomarker in cancer cells, due in part
to its broad tissue distributions and multiple functionalities
that may interfere with the judgmental accuracy. Since
downregulation of clathrin has been correlated with higher
periFN assembly and tumor malignancy by us and others, it
is worth further investigating whether such an inverse
relationship between FN/protease inhibitor and clathrin in
human cancers could clinically be incorporated into the
prognostic strategy for various cancer types.
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